UCalgary Study: Intermittent Fasting Effective for Crohn's Disease Weight Loss and Symptom Relief

Breakthrough Findings from UCalgary-Led Research

A groundbreaking randomized controlled trial conducted by researchers at the University of Calgary and the University of British Columbia Okanagan has demonstrated that time-restricted eating, a popular form of intermittent fasting, can significantly benefit individuals with Crohn's disease. Published in the prestigious journal Gastroenterology in early 2026, the study focused on overweight or obese adults whose Crohn's was in remission. Participants who limited their eating to an eight-hour window each day experienced notable improvements in disease activity, body composition, and inflammation markers, all without restricting calories or altering food quality.

This research highlights the innovative work emerging from Canadian higher education institutions, where clinician-scientists are bridging nutrition, gastroenterology, and microbiology to address chronic conditions like inflammatory bowel disease (IBD). Crohn's disease, characterized by chronic inflammation of the digestive tract, affects hundreds of thousands in Canada, making such studies particularly relevant.

Understanding Crohn's Disease in the Canadian Context

Crohn's disease is a type of IBD that can impact any part of the gastrointestinal tract, leading to symptoms like abdominal pain, diarrhea, fatigue, and weight loss. In Canada, the prevalence of IBD, including Crohn's, stands at approximately 320 per 100,000 people, or about 320,000 individuals as of recent estimates. Projections indicate this could rise to nearly 470,000 by the mid-2030s due to aging populations and increasing incidence rates.

Excess visceral fat, common in overweight Crohn's patients, exacerbates inflammation, reduces response to biologic therapies, and heightens surgical risks. Traditional management relies on medications, but up to 40 percent of patients do not achieve full remission. Lifestyle interventions like diet have been underexplored, prompting researchers at UCalgary's Cumming School of Medicine to investigate metabolic strategies.

The Mechanics of Time-Restricted Eating

Time-restricted eating (TRE), or 16:8 intermittent fasting, involves consuming all daily calories within an eight-hour period, followed by 16 hours of fasting. Water, black coffee, and tea are permitted during fasting windows. Unlike calorie counting, TRE emphasizes when you eat rather than what or how much, potentially aligning with circadian rhythms to optimize metabolism, gut health, and immune function.

In preclinical models, TRE has shown anti-inflammatory effects by modulating gut microbiota, reducing adipokine release from fat tissue, and improving insulin sensitivity. For Crohn's patients, where metabolic dysregulation fuels flares, this approach offers a non-pharmacological tool to support remission.

Detailed Methodology of the CD-FAST Trial

The CD-FAST trial (NCT05230160) was a 12-week pilot randomized controlled study enrolling 35 adults with quiescent Crohn's disease and body mass index (BMI) indicating overweight or obesity. Participants were randomized 1:1 to TRE (n=20) or standard care control (n=15). The TRE group fasted 16 hours daily, six days a week, maintaining their habitual diet.

Outcomes were assessed at baseline and week 12 using the Harvey-Bradshaw Index (HBI) for disease activity, dual-energy X-ray absorptiometry for visceral adipose tissue (VAT), serum adipokines and cytokines, fecal calprotectin, and 16S rRNA microbiota sequencing. Adherence was tracked via apps, reaching 95 percent in the TRE group. No changes in energy intake or diet quality (Mediterranean Diet Index) occurred between groups.

View full trial details on ClinicalTrials.gov

Key Results: Weight Loss and Clinical Improvements

TRE participants saw a BMI reduction of 0.9 kg/m² (P<0.001 vs. control's +0.6 kg/m²), equating to about 5.5 pounds lost versus 3.7 pounds gained in controls. HBI scores dropped by 2 points on average (P=0.02), reflecting a 40 percent decrease in disease activity, including halved stool frequency and abdominal discomfort.

• Visceral fat volume decreased significantly (P<0.05).
• Systemic inflammation markers like leptin fell sharply (P<0.001), alongside PAI-1 and adipsin.
• No differences in C-reactive protein or fecal calprotectin, indicating subtle shifts.

These changes persisted despite matched calorie intake, underscoring TRE's metabolic efficiency.

Metabolic, Inflammatory, and Microbiome Shifts

Beyond weight loss, TRE recalibrated immunometabolism. In those losing over 1 BMI unit, anti-inflammatory cytokines (IL-1RA, IL-4) correlated positively with fat loss (r=0.78, P<0.05), as did pro-inflammatory ones (IL-2, IL-12), suggesting balanced immune recalibration.

Gut microbiota trended toward greater diversity (P=0.06), with BMI loss linked to reduced Bacteroides ovatus and Escherichia/Shigella, and increased short-chain fatty acid producers like Butyricimonas synergistica. These taxa support gut barrier integrity, crucial for Crohn's remission.

Read the full study in Gastroenterology

Spotlight on UCalgary and UBCO Researchers

Principal investigator Dr. Maitreyi Raman, associate professor in UCalgary's Departments of Medicine and Community Health Sciences, directs ASCEND (Alberta’s Collaboration of Excellence in Nutrition in Digestive Diseases) at the Snyder Institute. Her work integrates clinical care with research on IBD nutrition.

Lead author Dr. Natasha Haskey, PhD, RD, from UBC Okanagan's Irving K. Barber Faculty of Science, specializes in microbiome-diet interactions. Funded by the Crohn's & Colitis Foundation's Litwin IBD Pioneers Grant and IMAGINE network, this collaboration exemplifies Canadian higher ed's strength in translational research.

For aspiring researchers, opportunities abound in higher ed research jobs at institutions like UCalgary, where clinician-scientists advance IBD therapies.

Implications for Crohn's Management and Beyond

This study positions TRE as a feasible adjunct to pharmacotherapy, potentially overcoming non-response rates. Low-cost and accessible, it empowers patients while alleviating healthcare burdens amid rising IBD prevalence.

In higher education, it underscores nutrition's role in chronic disease, inspiring curricula in dietetics, gastroenterology, and microbiology programs across Canada. Faculty exploring similar interventions can find career advice at higher ed career advice.

UCalgary news release

Potential Challenges and Safety Considerations

While adherence was high, TRE may not suit all, especially those with eating disorders or malnutrition risks. The pilot's small size and short duration limit generalizability; no adverse events were reported, but monitoring is essential.

Patients should consult gastroenterologists before starting, integrating TRE with medications. Canadian universities like UCalgary emphasize personalized approaches in their IBD clinics.

Future Directions in Canadian IBD Research

Larger trials are planned to assess long-term remission, mechanisms, and ulcerative colitis applicability. UCalgary's Snyder Institute and UBCO's biology department aim to dissect TRE-microbiome-immune axes using advanced sequencing.

This aligns with national priorities; explore Canada university jobs for roles in digestive health research. Related Canadian higher ed trends highlight funding needs for such vital studies.

Practical Insights for Patients and Healthcare Providers

• Start with a 12-hour fast, gradually extending to 16:8.
• Prioritize nutrient-dense meals in the eating window: lean proteins, fibers, omega-3s.
• Track symptoms via apps; pair with standard IBD care.
• Collaborate with registered dietitians, abundant in Canadian higher ed programs.

For professors and students, this study offers teaching modules on evidence-based nutrition. Check university jobs for openings in health sciences faculties.

Photo by Towfiqu barbhuiya on Unsplash

Broader Impact on Higher Education and Public Health

UCalgary's output reinforces Canada's leadership in IBD research, attracting grants and talent. Institutions foster interdisciplinary teams, vital for complex diseases. Patients and academics alike benefit from resources like Rate My Professor to connect with experts.

As IBD surges, university-driven innovations like TRE could transform management, reducing hospitalizations and enhancing quality of life. Explore higher ed jobs, research jobs, and career advice to contribute.